Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Two-Arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QoL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis Who Are Transitioning From Rebif (Interferon Beta-1a) to Rebif New Formulation (RNF).

Next Previous
X
Search
Trial Profile

A Randomized, Multicenter, Two-Arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QoL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis Who Are Transitioning From Rebif (Interferon Beta-1a) to Rebif New Formulation (RNF).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms REQOL
  • Sponsors EMD Serono

    • Most Recent Events

    • 24 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Planned end date changed from 1 Aug 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Actual patient number (232) and additional lead trial investigator (Dangond F) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top